INTS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 125800 min ago

@ $3.41

Išleistas: 12 vas. 2024 @ 21:19

Grąža: 10.26%

Ankstesnis signalas: vas. 8 - 19:41

Ankstesnis signalas: Pardavimas

Grąža: -5.28 %

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
Šios dienos apimtis	4 112.00
Vidutinė apimtis	38 032.00
Rinkos kapitalizacija	51.55M
EPS	$0 ( 2024-04-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.72
ATR14	$0.0690 (1.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)
2024-03-06	Leahy Emer	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Goldberg Mark A	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Donovan Daniel	Buy	50 000	Stock Option (right to buy Common Stock)
2024-03-06	Bender Lewis H	Buy	464 805	Stock Option (right to buy Common Stock)

INSIDER POWER
57.42
Last 23 transactions
Buy: 803 379 \| Sell: 331 500

Intensity Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Intensity Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
Pajamos:	$0
Bruto pelnas:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
Pajamos:	$0
Bruto pelnas:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.